Dopamine involved in recognizing emotions

Ball-and-stick model of the dopamine molecule, a neurotransmitter that affects the brain's reward and pleasure centers. Credit: Jynto/Wikipedia

The neurotransmitter dopamine, famous for its role in reward, is also involved in recognizing emotions, according to new research published in JNeurosci.

People with disrupted , like in Parkinson's disease and schizophrenia, often struggle with aspects of social cognition. Yet the link between and specific social behaviors remained elusive, in part due to mixed results from studies that did not account for in dopamine levels.

In a study by Schuster et al., healthy participants took haloperidol—a dopamine receptor inhibitor—on one day and a placebo pill on another before completing an emotion recognition task. They assessed videos of people expressing an emotion through their posture and gait (i.e., slow movements for sadness, quick, jerky movements for anger). The researchers also indirectly measured each person's baseline dopamine levels by testing their working memory. The effects of haloperidol varied in each person depending on their baseline dopamine levels. In people with low dopamine, the drug increased their ability to recognize emotions, while in people with high dopamine, the drug impaired their ability.

Examples of the stimuli used in the study. From left to right: Happy, angry and sad emotional states conveyed in point-light-displays of walking bodies. Credit: Stimuli created by Edey et al (2017) adapted from Nackaerts et al. (2012)

Future work will examine how changes in dopamine levels in disorders like Parkinson's disease contribute to social cognition impairments.

More information: Dopaminergic modulation of dynamic emotion perception, JNeurosci (2022). DOI: 10.1523/JNEUROSCI.2364-21.2022

Journal information: Journal of Neuroscience
Citation: Dopamine involved in recognizing emotions (2022, May 2) retrieved 20 July 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Dopamine agonists and dopamine reuptake inhibitors provide similar quality of life for Parkinson disease patients


Feedback to editors